Itulazax (Betula Verrucosa (108))

The Betula verrucosa extract in Itulazax provides repeated, controlled exposure to the birch pollen allergen via the sublingual route. This exposure promotes the generation of regulatory T cells and shifts antibody production from IgE toward IgG4, thereby decreasing hypersensitivity and mitigating allergic responses upon natural pollen exposure.

The dosing regimen for Itulazax is individualized and determined by the prescribing physician based on the patient’s sensitivity, age, and clinical response. The prescriber selects the appropriate starting concentration and titration schedule, which may be adjusted during the course of therapy.

Safety data for Itulazax in pregnancy and lactation are limited. It should only be used when the potential therapeutic benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the Itulazax product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Itulazax delivers a standardized Betula verrucosa extract via the sublingual route, offering a non‑injectable alternative to traditional subcutaneous immunotherapy. Compared with other sublingual products, Itulazax provides comparable efficacy in inducing tolerance, while allowing self‑administration at home after the initial supervised dose, potentially improving patient convenience and adherence.

Itulazax should be stored at ambient temperature, preferably below 25 °C, in its original packaging. The product must be protected from moisture, direct sunlight and extreme temperature fluctuations. Do not refrigerate or freeze the medication, and keep it out of reach of children.

Itulazax is administered sublingually. The patient places the prescribed dose under the tongue and holds it there for the time specified by the prescriber, usually several minutes, before swallowing. The initial dose is typically given under medical supervision, after which subsequent doses can be taken at home as directed.

The most serious risks of Itulazax include systemic allergic reactions such as anaphylaxis, angioedema, and severe asthma exacerbations. Patients should be educated to recognize early signs of these reactions and seek immediate medical attention. Emergency medication, such as epinephrine auto‑injectors, should be readily available for individuals at risk.

Itulazax is contraindicated in individuals with a known severe anaphylactic reaction to Betula verrucosa or other birch pollen allergens, as well as those who have experienced life‑threatening systemic reactions to previous allergen immunotherapy. Patients with uncontrolled asthma, severe cardiovascular disease, or those taking beta‑blockers without appropriate medical supervision should also avoid its use.